drugset / Trial / NCT05947747
Safety and Efficacy of EXO-CD24 in Preventing Clinical Deterioration in Patients With Mild-Moderate ARDS
RandomizedParallel-groupSingle-blindTreatment
Summary
This is phase IIb, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 of one dose 10\^10 exosome particles, to Prevent Clinical Deterioration in Patients with Mild-Moderate ARDS
Timeline
- Start
- 2023-07-04
- Primary completion
- 2025-12-20
- Completion
- 2025-12-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXO-CD24 | Other / unclassified | 1e+10 unknown | Inhaled |